PP190 Real-world evaluation of patient characteristics, and treatment patterns in locally advanced or metastatic urothelial cancer following approval of maintenance therapy in South Korea

ESMO Open 2026 Open access

Read full text
Authors: Li-Jen Cheng, Eo Jin Kim, Kyungah Park, David Nimke, Eunjee Cho, Mia Unsworth, Maria Walley, Amber Simpson
DOI: 10.1016/j.esmoop.2025.105985
Cited by: 0

Abstract

Platinum-based chemotherapy (PBC) has been recommended as first-line (1L) therapy for eligible patients (pts) with locally advanced or metastatic urothelial cancer (Ia/mUC). In South Korea, the Ia/mUC treatment landscape has evolved over the past five yrs with approval of new treatment options, including programmed death-ligand 1 (PD-L1) inhibitors (ie, avelumab maintenance), and enfortumab vedotin (EV). This study described the pt characteristics and Ia/mUC treatment landscape in South Korea.

Fields of Study & Subjects

Bladder and Urothelial Cancer Treatments Urinary Tract Infections Management Urinary and Genital Oncology Studies

Publication details

Journal / source
ESMO Open
Volume
11
Pages
105985–105985
Publication date
1 February 2026
Language
EN